The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 02, 2020

Filed:

Aug. 10, 2018
Applicant:

Bausch & Lomb Incorporated, Rochester, NY (US);

Inventors:

Ivan M. Nuñez, Penfield, NY (US);

Lynn Coullard, Williamson, NY (US);

Daniel J. Hook, Fairport, NY (US);

Robert B. Steffen, Naples, FL (US);

Daniel M. Ammon, Webster, NY (US);

Jennifer M. Hunt, Lake Grove, NY (US);

Analuz Mark, Spencerport, NY (US);

Assignee:

Bausch & Lomb Incorporated, Rochester, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G02B 1/04 (2006.01); B29D 11/00 (2006.01); C08F 293/00 (2006.01); C08L 33/12 (2006.01); B29K 105/00 (2006.01); C08F 22/28 (2006.01); C08F 20/12 (2006.01); C08F 22/26 (2006.01); C08F 20/14 (2006.01); B29K 33/00 (2006.01); C08F 22/10 (2006.01);
U.S. Cl.
CPC ...
B29D 11/00038 (2013.01); C08L 33/12 (2013.01); B29D 11/00067 (2013.01); B29K 2033/00 (2013.01); B29K 2033/08 (2013.01); B29K 2033/12 (2013.01); B29K 2105/0061 (2013.01); B29K 2833/12 (2013.01); B29K 2995/0092 (2013.01); C08F 20/12 (2013.01); C08F 20/14 (2013.01); C08F 22/1006 (2020.02); C08F 22/26 (2013.01); C08F 22/28 (2013.01); C08F 293/005 (2013.01); G02B 1/043 (2013.01);
Abstract

An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer ('RAFT') agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.


Find Patent Forward Citations

Loading…